Anti-CD22 chimeric antigen receptors
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Jan 16, 2018
Grant Date -
Sep 18, 2014
app pub date -
Oct 19, 2012
filing date -
Oct 20, 2011
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The disclosure provides a chimeric antigen receptor (CAR) comprising a) an antigen binding domain of HA22, a transmembrane domain, and an intracellular T cell signaling domain; or b) an antigen binding domain of BL22, a transmembrane domain, and an intracellular T cell signaling domain comprising CD28 and/or CD137. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.
First Claim
Other Claims data not available
Family
International Classification(s)
- 2012 Application Filing Year
- A61K Class
- 11964 Applications Filed
- 9694 Patents Issued To-Date
- 81.03 % Issued To-Date
Cited Art Landscape
Patent Citation Ranking
- 8 Citation Count
- A61K Class
- 50.93 % this patent is cited more than
- 7 Age
Maintenance Fees
| Fee | Large entity fee | small entity fee | micro entity fee | due date |
|---|---|---|---|---|
| 7.5 Year Payment | $3600.00 | $1800.00 | $900.00 | Jul 16, 2025 |
| 11.5 Year Payment | $7400.00 | $3700.00 | $1850.00 | Jul 16, 2029 |
